Soros Fund Management’s BridgeBio Oncology BBOT Stock Holding History

Soros Fund Management’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-150,000	Closed	-$1.7M	–	269
2025 Q1	$1.7M	Sell	150,000 -325,114	-68%	-$3.49M	0.03%	193
2024 Q4	$4.99M	Buy	475,114 +114	+0%	+$1.2K	0.08%	157
2024 Q3	$4.96M	Hold	475,000	–	–	0.07%	134
2024 Q2	$4.85M	Hold	475,000	–	–	0.09%	139
2024 Q1	$4.94M	Buy	+475,000	New	+$4.92M	0.08%	148

Other funds holding BBOT

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HCI

Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return

Soros Fund Management's BBOT Position: Q2 2025 in Review

Soros Fund Management sold out of BridgeBio Oncology (BBOT) in Q2 2025, closing a stake of 150,000 shares — an estimated $1.7M sold.

Soros Fund Management first reported a position in BBOT in Q1 2024 and held it in 5 quarters. The position peaked at $4.99M in Q4 2024. 34 funds tracked by Wall St. Rank hold BBOT as of Q2 2025.

Soros Fund Management reported no remaining BridgeBio Oncology position as of Q2 2025 after selling out during the quarter.
Soros Fund Management sold 150,000 BridgeBio Oncology shares in Q2 2025, an estimated $1.7M.
Soros Fund Management first reported a position in BridgeBio Oncology in Q1 2024 and held it in 5 quarters.
Soros Fund Management's BridgeBio Oncology position peaked at $4.99M in Q4 2024.
34 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2025.

Based on Soros Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.